Ayisha Sharma
Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from the University College London. Ayisha is especially interested in the clinical landscape for rare diseases. Outside of work, she has written for several lifestyle and culture publications including The Kraze and M&S Vmag.
Latest From Ayisha Sharma
Evotec Adds To Spate Of Metabolic Deals With Eli Lilly Collaboration
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Eli Lilly to develop kidney disease and diabetes assets.
Five Pivotal Trial Read-Outs To Look Out For In Early 2022
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
‘Challenges Ahead’ For Cell And Gene Therapy, Notes Catapult’s New Chairman McCubbin
The ex-GSK supply head Ian McCubbin will join the independent UK organization aimed at advancing cell and gene therapies, but notes issues with scale and manufacturing ahead.
‘Challenges Ahead’ For Cell And Gene Therapy, Notes Catapult’s New Chairman McCubbin
The ex-GSK supply head Ian McCubbin will join the independent UK organization aimed at advancing cell and gene therapies, but notes issues with scale and manufacturing ahead.
AstraZeneca Plans To Drug The Undruggable With Scorpion Partnership
The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.
Aldeyra Therapeutics Eyes First Line Market As Phase II Dry Eye Candidate Impresses
The firm’s lead asset, reproxalap, one-upped Novartis’s Xiidra in a mid-stage ophthalmology study, signalling its first-line promise in a market ridden with compliance issues.